It is looking likely that another late-stage candidate for Alzheimer’s disease will fail to make it past Phase III trials, with vTv Therapeutics’ experimental therapy the latest in a long line to miss its targets. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/vtv_reports_alzheimers_candidate_failure_1231331AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_ups_stake_in_moderna_1095937GlaxoSmithKline and Kymera have sealed a pact to work together on the discovery of new medicines based on protein degradation. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/gsk_and_kymera_team_up_for_protein_degradation_alliance_1230453US regulators have awarded orphan drug status to Shire's investigational therapy, SHP647, for the treatment of paediatric patients with moderately to severely active Crohn's disease. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shires_shp647_bags_another_orphan_badge_1222264Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/biogen_buys_pfizers_schizophrenia_drug_1227136Global investment group Advent International says it has entered into exclusive negotiations to buy Sanofi’s generics arm Zentiva for 1.9 billion Euros ($2.4 billion). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi_to_sell_generics_unit_for_1.9_billion_euros_1232103Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bms_ties_with_janssen_on_factor_xia_inhibitor_programme_1232116Shire has unveiled plans to split its operations into two separate entities - a neuroscience division and rare diseases one, and will later decide whether they should be listed independently. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_to_split_operations_in_two_1216109GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/gw_completes_epidiolex_submission_1209905Dublin, Ireland-based Shire is selling its oncology unit to France’s Servier in a deal worth $2.4 billion. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_sells_oncology_unit_to_servier_for_$2.4bn_1231953
